Superbugs weren’t created in a single event. They emerged gradually, driven by decades of antibiotic overuse in medicine, agriculture, and manufacturing that gave bacteria constant opportunities to evolve resistance. The first resistant strain appeared in 1940, just a year before penicillin was even tested in humans, and the problem has accelerated ever since. Today, antibiotic-resistant bacteria directly kill an estimated 1.27 million people worldwide each year.
Resistance Started Almost Immediately
The story begins with penicillin. In 1940, researchers Abraham and Chain reported that an E. coli strain could produce an enzyme that destroyed penicillin, rendering the drug useless against it. This was before penicillin had even been given to a patient in a clinical trial (that happened in early 1941) and years before mass production ramped up for World War II in 1944. Bacteria, in other words, had resistance tools before humans even started widely using the drugs.
This makes sense when you consider that antibiotics aren’t a human invention from scratch. Many are derived from compounds that soil fungi and bacteria have been producing for millions of years to compete with each other. Resistance genes already existed in nature. What human activity did was put massive, sustained pressure on bacterial populations, selecting for the rare organisms that carried those genes and giving them an enormous survival advantage.
How Bacteria Share Resistance
What makes superbugs especially dangerous is that bacteria don’t just pass resistance to their offspring. They can share resistance genes sideways, between completely unrelated species, through a process called horizontal gene transfer. This happens in three main ways.
- Conjugation: One bacterium physically connects to another and passes a small loop of DNA (a plasmid) carrying resistance genes directly to it. Think of it as bacteria handing off a USB drive.
- Transduction: Viruses that infect bacteria accidentally package resistance genes and carry them into new bacterial cells.
- Transformation: Bacteria absorb free-floating DNA from their environment, often released by dead bacteria nearby.
These mechanisms mean a harmless gut bacterium that develops resistance to an antibiotic can pass that ability to a dangerous pathogen it happens to encounter. One species figures out the trick, and many others can benefit.
Medical Overuse Fueled the Problem
Every time you take an antibiotic, you kill off susceptible bacteria and leave behind the small number that have some natural resistance. Those survivors multiply and become the dominant population. When antibiotics are prescribed for infections they can’t treat, like colds and flu caused by viruses, this selection pressure happens for zero benefit.
The CDC estimates that at least 28% of antibiotics prescribed in outpatient settings in the United States are unnecessary. Multiply that across billions of prescriptions over decades, and you get an enormous, pointless acceleration of resistance. Hospitals compound the problem further: the intensive use of antibiotics in clinical settings creates local hotspots where resistant bacteria thrive and spread between patients, particularly through biofilms.
Biofilms: Resistance Factories in Hospitals
Biofilms are dense communities of bacteria that coat surfaces like catheters, ventilator tubes, and surgical implants. The bacteria encase themselves in a sticky, self-produced matrix that antibiotics struggle to penetrate. Inside these colonies, bacteria live in close quarters, which dramatically increases the rate of conjugation, the direct DNA-swapping process that spreads resistance genes. A bacterium that enters a biofilm susceptible to antibiotics can emerge resistant after picking up genes from its neighbors.
This is why hospital-acquired infections are so frequently caused by resistant organisms. The combination of heavy antibiotic use, vulnerable patients, and biofilm-coated devices creates ideal conditions for superbugs to develop and spread.
Agriculture Uses Most of the World’s Antibiotics
Roughly 73% of all antibiotic consumption globally is attributable to the meat industry. For decades, farmers used antibiotics not just to treat sick animals but to promote faster growth in healthy livestock. Low, continuous doses of antibiotics in feed and water are particularly effective at breeding resistance because they don’t kill bacteria outright. Instead, they create a constant, low-grade pressure that selects for resistant strains over time.
Global veterinary antibiotic consumption is projected to reach about 104,000 tonnes by 2030, an 11.5% increase from 2017 levels. Resistant bacteria from animal operations enter the environment through manure, runoff, and contaminated meat, where they can transfer their resistance genes to bacteria that infect humans. Many countries have now banned growth-promotion use of antibiotics in livestock, but enforcement varies widely and the practice continues in much of the world.
Pharmaceutical Pollution and Environmental Hotspots
Factory runoff is an underappreciated driver of resistance. Pharmaceutical manufacturing facilities, particularly in countries with less stringent environmental regulation, discharge elevated levels of antibiotic compounds into rivers and lakes. These waterways then become breeding grounds where environmental bacteria are constantly exposed to sub-lethal antibiotic concentrations, the exact conditions that accelerate resistance evolution.
Wastewater treatment plants, hospital effluent systems, and aquaculture operations function as similar hotspots. Resistant bacteria and the genes they carry circulate through these water systems and spread into broader ecosystems, including drinking water sources. The resistance genes that develop in an industrial wastewater pond can eventually end up in a pathogen infecting someone who has never taken an antibiotic.
The NDM-1 Enzyme: A Case Study
One of the most alarming superbugs illustrates how these forces converge. In 2008, doctors identified a Swedish patient who had been hospitalized in New Delhi with a urinary tract infection caused by a strain of Klebsiella pneumoniae that resisted carbapenems, a class of antibiotics reserved as a last resort when nothing else works. The bacterium carried a gene coding for an enzyme now called NDM-1 (New Delhi metallo-beta-lactamase).
NDM-1 uses zinc atoms in its active site to physically break open the core ring structure of nearly all commonly used antibiotics in the beta-lactam family, which includes penicillins, cephalosporins, and carbapenems. Because the gene for NDM-1 sits on a plasmid, it transfers easily between bacterial species through conjugation. Within a few years of its discovery, NDM-1-carrying bacteria had been found on every inhabited continent, in clinical settings and in environmental water samples alike.
The Drug Pipeline Has Nearly Dried Up
What makes the superbug crisis especially urgent is that new antibiotics aren’t keeping pace. Between 1940 and 1962, more than 20 entirely new classes of antibiotics reached the market. Since then, only two new classes have been approved. The economics work against development: antibiotics are taken for short courses, and any truly effective new drug would be held in reserve to slow resistance, meaning low sales. Most pharmaceutical companies have largely abandoned antibiotic research in favor of more profitable drugs.
This means the antibiotics we rely on today are mostly refinements of classes discovered more than 60 years ago. Bacteria have had decades to evolve workarounds for each one. When a pathogen accumulates resistance to multiple drug classes, the result is what gets labeled a superbug: an infection with few or no remaining treatment options. The gap between bacterial evolution and human drug development continues to widen, and without significant changes in how antibiotics are used and developed, the toll of 1.27 million annual deaths is projected to grow substantially in the coming decades.